GlassScriptPhysician profile
Ross M Michels
NPI 1679740211
$12,657.25
in general payments reported to CMS, 2019-2025
49 companies · $2,302 in 2025
The $2,302 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,025 · 2020: $557 · 2021: $975 · 2022: $1,555 · 2023: $3,197 · 2024: $3,047 · 2025: $2,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,310 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,310.48 |
| Education | $235.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,385.99 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $1,173.08 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Rigel Pharmaceuticals, INC. | $822.57 | 2020-2025 | Rezlidhia, Tavalisse, Rezlidhia |
| Bayer Healthcare Pharmaceuticals INC. | $689.82 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $657.13 | 2019-2025 | Opdivo, Abecma, Opdualag |
| Merck Sharp & Dohme LLC | $634.15 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Beigene USA, INC. | $626.36 | 2022-2024 | Brukinsa |
| Janssen Biotech, INC. | $597.52 | 2022-2025 | Rybrevant, Carvykti, Erleada |
| Gilead Sciences, INC. | $387.39 | 2023-2025 | Trodelvy |
| Kite Pharma, INC. | $368.08 | 2019-2023 | Yescarta |
| Galvanize Therapeutics, INC | $365.60 | 2023-2024 | Aliya System |
| Amgen INC. | $363.23 | 2019-2024 | Lumakras, Xgeva, Vectibix |
| Pfizer INC. | $357.46 | 2019-2024 | |
| Seagen INC. | $326.79 | 2021-2023 | Tukysa, Adcetris |
| Stemline Therapeutics INC. | $298.23 | 2022-2024 | Orserdu |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Michels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.